此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Nemtabrutinib (MK-1026) 在血液系统恶性肿瘤 (MK-1026-003) 参与者中的疗效和安全性

2026年10月23日 更新者:Merck Sharp & Dohme LLC

评估 MK-1026 在血液系统恶性肿瘤参与者中的疗效和安全性的 2 期研究

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

研究概览

详细说明

This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and Cohort Expansion (Part 2). Following determination of the recommended phase 2 dose (RP2D) in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A to H).

研究类型

介入性

注册 (估计的)

490

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Anhui
      • Hefei、Anhui、中国、230071
        • 主动,不招人
        • Anhui Provincial Hospital ( Site 2808)
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100191
        • 招聘中
        • Peking University Third Hospital-Hematology ( Site 2827)
        • 接触:
          • Study Coordinator
          • 电话号码:010-82266699
    • Chongqing Municipality
      • Chongqing、Chongqing Municipality、中国、400072
        • 主动,不招人
        • The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)
    • Guangdong
      • Guangzhou、Guangdong、中国、510060
        • 主动,不招人
        • Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)
    • Guangxi
      • Liuzhou、Guangxi、中国、545006
        • 招聘中
        • Liuzhou People's Hospital ( Site 2817)
        • 接触:
          • Study Coordinator
          • 电话号码:+8607722662950
      • Nanning、Guangxi、中国、530028
        • 招聘中
        • Guangxi Medical University Cancer Hospital ( Site 2814)
        • 接触:
          • Study Coordinator
          • 电话号码:+8607715323174
    • Henan
      • Zhengzhou、Henan、中国、450008
        • 招聘中
        • Henan Cancer Hospital-hematology department ( Site 2802)
        • 接触:
          • Study Coordinator
          • 电话号码:0371-65588007
    • Hubei
      • Wuhan、Hubei、中国、430022
        • 招聘中
        • Wuhan Union Hospital ( Site 2816)
        • 接触:
          • Study Coordinator
          • 电话号码:+8618627091655
    • Hunan
      • Changsha、Hunan、中国、410011
        • 招聘中
        • The Second Xiangya Hospital of Central South University ( Site 2820)
        • 接触:
          • Study Coordinator
          • 电话号码:+8613975806137
      • Changsha、Hunan、中国、410013
        • 招聘中
        • Hunan Cancer Hospital ( Site 2822)
        • 接触:
          • Study Coordinator
          • 电话号码:0731-88651669
    • Jiangsu
      • Nanjing、Jiangsu、中国、210029
        • 招聘中
        • Jiangsu Province Hospital ( Site 2823)
        • 接触:
          • Study Coordinator
          • 电话号码:025-86211033
      • Xuzhou、Jiangsu、中国、221000
        • 完全的
        • The Affiliated Hospital of Xuzhou Medical College ( Site 2818)
    • Jiangxi
      • Nanchang、Jiangxi、中国、330006
        • 招聘中
        • The First Affiliated Hospital of Nanchang University ( Site 2815)
        • 接触:
          • Study Coordinator
          • 电话号码:13970038386
    • Jilin
      • Changchun、Jilin、中国、130021
        • 招聘中
        • The First Hospital of Jilin University-Hematology ( Site 2803)
        • 接触:
          • Study Coordinator
          • 电话号码:0431-88786014
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200032
        • 招聘中
        • Fudan University Shanghai Cancer Center ( Site 2801)
        • 接触:
          • Study Coordinator
          • 电话号码:+8602164175590
      • Shanghai、Shanghai Municipality、中国、200040
        • 招聘中
        • Huashan Hospital, Fudan University ( Site 2821)
        • 接触:
          • Study Coordinator
          • 电话号码:021-52889999
    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • 招聘中
        • West China Hospital Sichuan University ( Site 2810)
        • 接触:
          • Study Coordinator
          • 电话号码:+86028-85422114
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、301617
        • 招聘中
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio ( Site 2800)
        • 接触:
          • Study Coordinator
          • 电话号码:+8615900265415
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310002
        • 招聘中
        • The First Affiliated Hospital, Zhejiang University ( Site 2826)
        • 接触:
          • Study Coordinator
          • 电话号码:057187236114
    • Central Jutland
      • Aarhus N、Central Jutland、丹麦、8200
        • 完全的
        • Aarhus University Hospital ( Site 0702)
    • North Denmark
      • Aalborg、North Denmark、丹麦、9000
        • 招聘中
        • Aalborg Universitetshospital ( Site 0703)
        • 接触:
          • Study Coordinator
          • 电话号码:+45 97660000
    • Region Sjælland
      • Koege、Region Sjælland、丹麦、4600
        • 招聘中
        • Sjællands Universitetshospital Køge ( Site 0701)
        • 接触:
          • Study Coordinator
          • 电话号码:+45 46323200
    • Region Syddanmark
      • Odense C、Region Syddanmark、丹麦、5000
        • 完全的
        • Odense University Hospital ( Site 0705)
      • Kyiv、乌克兰、03022
        • 招聘中
        • National Cancer Institute ( Site 2507)
        • 接触:
          • Study Coordinator
          • 电话号码:+380672091427
    • Cherkasy Oblast
      • Cherkassy、Cherkasy Oblast、乌克兰、18009
        • 主动,不招人
        • MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2509)
    • Ivano-Frankivsk Oblast
      • Ivano-Frankivsk、Ivano-Frankivsk Oblast、乌克兰、76008
        • 完全的
        • Communal non-profit enterprise "Regional clinical hospital o-Hematology Department ( Site 2510)
    • Lviv Oblast
      • Lviv、Lviv Oblast、乌克兰、79044
        • 招聘中
        • Instit. of Blood Transfusion Medicine of the National Academy ( Site 2506)
        • 接触:
          • Study Coordinator
          • 电话号码:+380322352276
      • Afula、以色列、1834111
        • 招聘中
        • Ha Emek Medical Center ( Site 1305)
        • 接触:
          • Study Coordinator
          • 电话号码:972-46494052
      • Beersheba、以色列、8410101
        • 招聘中
        • Soroka Medical Center ( Site 1307)
        • 接触:
          • Study Coordinator
          • 电话号码:+97286403827
      • Haifa、以色列、3109601
        • 招聘中
        • Rambam Medical Center ( Site 1301)
        • 接触:
          • Study Coordinator
          • 电话号码:+97247772547
      • Jerusalem、以色列、9112001
        • 招聘中
        • Hadassah Ein Karem Jerusalem ( Site 1300)
        • 接触:
          • Study Coordinator
          • 电话号码:+97226778180
      • Ramat Gan、以色列、5262001
        • 招聘中
        • Chaim Sheba Medical Center ( Site 1302)
        • 接触:
          • Study Coordinator
          • 电话号码:+97235308401
      • Rehovot、以色列、76100
        • 招聘中
        • Kaplan Medical Center ( Site 1304)
        • 接触:
          • Study Coordinator
          • 电话号码:+97289441726
      • Tel Aviv、以色列、6423906
        • 招聘中
        • Sourasky Medical Center ( Site 1303)
        • 接触:
          • Study Coordinator
          • 电话号码:+97236973782
    • Alberta
      • Calgary、Alberta、加拿大、T2N 5G2
        • 招聘中
        • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)
        • 接触:
          • Study Coordinator
          • 电话号码:4035213723
    • Ontario
      • Ottawa、Ontario、加拿大、K1H 8L6
        • 招聘中
        • The Ottawa Hospital ( Site 0404)
        • 接触:
          • Study Coordinator
          • 电话号码:613 737-7700
      • Toronto、Ontario、加拿大、M5G 2M9
        • 招聘中
        • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)
        • 接触:
          • Study Coordinator
          • 电话号码:416-946-2827
    • Quebec
      • Montreal、Quebec、加拿大、H3T 1E2
        • 招聘中
        • Jewish General Hospital ( Site 0400)
        • 接触:
          • Study Coordinator
          • 电话号码:5143408222 x 24572
      • Montreal、Quebec、加拿大、H1T 2M4
        • 招聘中
        • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)
        • 接触:
          • Study Coordinator
          • 电话号码:5142523400
      • Budapest、匈牙利、1122
        • 招聘中
        • Orszagos Onkologiai Intezet ( Site 1200)
        • 接触:
          • Study Coordinator
          • 电话号码:+3612248600
    • Baranya
      • Pécs、Baranya、匈牙利、7624
        • 招聘中
        • Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar ( Site 1202)
        • 接触:
          • Study Coordinator
          • 电话号码:+3672536000
    • Hajdú-Bihar
      • Debrecen、Hajdú-Bihar、匈牙利、4032
        • 招聘中
        • Debreceni Egyetem Klinikai Kozpont ( Site 1201)
        • 接触:
          • Study Coordinator
          • 电话号码:+3652255196
    • Szabolcs-Szatmár-Bereg
      • Nyíregyháza、Szabolcs-Szatmár-Bereg、匈牙利、4400
        • 招聘中
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1206)
        • 接触:
          • Study Coordinator
          • 电话号码:+3642599700
      • Ankara、土耳其(türkiye)、06590
        • 招聘中
        • Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2400)
        • 接触:
          • Study Coordinator
          • 电话号码:+903125957099
      • Istanbul、土耳其(türkiye)、34365
        • 完全的
        • VKV Amerikan Hastanesi ( Site 2403)
      • Istanbul、土耳其(türkiye)、34381
        • 招聘中
        • Sisli Florence Nightingale Hastanesi ( Site 2407)
        • 接触:
          • Study Coordinator
          • 电话号码:+90 542 502 50 75
      • Izmir、土耳其(türkiye)、35340
        • 主动,不招人
        • Dokuz Eylül Üniversitesi-Hematology ( Site 2402)
    • Istanbul
      • Stanbul、Istanbul、土耳其(türkiye)、34214
        • 主动,不招人
        • Mega Medipol-Hematology ( Site 2406)
      • Rio de Janeiro、巴西、20231-050
        • 招聘中
        • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)
        • 接触:
          • Study Coordinator
          • 电话号码:+552132076564
      • São Paulo、巴西、01321-001
        • 招聘中
        • Hospital Paulistano - Amil Clinical Research ( Site 0311)
        • 接触:
          • Study Coordinator
          • 电话号码:+551130161340
      • São Paulo、巴西、01321-001
        • 主动,不招人
        • BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)
    • São Paulo
      • São Paulo、São Paulo、巴西、05403-000
        • 招聘中
        • Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)
        • 接触:
          • Study Coordinator
          • 电话号码:551145737543
    • Baden-Wurttemberg
      • Ulm、Baden-Wurttemberg、德国、89081
        • 招聘中
        • Universitaetsklinikum Ulm. ( Site 0906)
        • 接触:
          • Study Coordinator
          • 电话号码:+ 49 731 500 45901
    • North Rhine-Westphalia
      • Cologne、North Rhine-Westphalia、德国、50937
        • 招聘中
        • Universitaetsklinikum Koeln ( Site 0901)
        • 接触:
          • Study Coordinator
          • 电话号码:+4922147897046
      • Siegen、North Rhine-Westphalia、德国、57072
        • 完全的
        • St. Marien-Krankenhaus Siegen ( Site 0914)
    • Saxony
      • Dresden、Saxony、德国、01307
        • 招聘中
        • Universitaetsklinikum Carl Gustav Carus ( Site 0902)
        • 接触:
          • Study Coordinator
          • 电话号码:0049 351 458 5692
      • Bari、意大利、70124
        • 完全的
        • Istituto Tumori Giovanni Paolo II ( Site 1409)
      • Bologna、意大利、40138
        • 招聘中
        • A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1400)
        • 接触:
          • Study Coordinator
          • 电话号码:+390516363680
      • Brescia、意大利、25123
        • 招聘中
        • ASST Spedali Civili di Brescia ( Site 1408)
        • 接触:
          • Study Coordinator
          • 电话号码:+39 0303996416
      • Milan、意大利、20132
        • 招聘中
        • IRCCS Ospedale San Raffaele ( Site 1402)
        • 接触:
          • Study Coordinator
          • 电话号码:00390226434797
      • Naples、意大利、80131
        • 招聘中
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1403)
        • 接触:
          • Study Coordinator
          • 电话号码:+39 0815903 382
      • Pavia、意大利、27100
        • 招聘中
        • Fondazione IRCCS Policlinico San Matteo ( Site 1407)
        • 接触:
          • Study Coordinator
          • 电话号码:+39 0382503084
      • Reggio Emilia、意大利、42123
        • 招聘中
        • IRCCS - Arcispedale Santa Maria Nuova ( Site 1405)
        • 接触:
          • Study Coordinator
          • 电话号码:+39 0522295654
      • Roma、意大利、00161
        • 完全的
        • Policlinico Umberto I ( Site 1404)
      • Hradec Králové、捷克语、500 05
        • 招聘中
        • Fakultni nemocnice Hradec Kralove ( Site 0601)
        • 接触:
          • Study Coordinator
          • 电话号码:+420495832159
    • Brno-mesto
      • Brno、Brno-mesto、捷克语、625 00
        • 招聘中
        • Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0600)
        • 接触:
          • Study Coordinator
          • 电话号码:+420532233642
      • Paris、法国、75010
        • 招聘中
        • Hopital Saint Louis ( Site 0805)
        • 接触:
          • Study Coordinator
          • 电话号码:+33142499236
    • Alpes-Maritimes
      • Nice、Alpes-Maritimes、法国、06202
        • 招聘中
        • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0810)
        • 接触:
          • Study Coordinator
          • 电话号码:+33 4 92 03 57 85
    • Auvergne-Rhône-Alpes
      • Pierre-Bénite、Auvergne-Rhône-Alpes、法国、69495
        • 招聘中
        • Centre Hospitalier Lyon-Sud ( Site 0804)
        • 接触:
          • Study Coordinator
          • 电话号码:+33478864348
    • Bouches-du-Rhone
      • Marseille、Bouches-du-Rhone、法国、13009
        • 招聘中
        • Institut Paoli-Calmettes ( Site 0803)
        • 接触:
          • Study Coordinator
          • 电话号码:+33491223537
    • Yvelines
      • Le Chesnay、Yvelines、法国、78150
        • 完全的
        • Centre Hospitalier de Versailles ( Site 0809)
    • Lesser Poland Voivodeship
      • Krakow、Lesser Poland Voivodeship、波兰、30-727
        • 招聘中
        • Pratia MCM Krakow ( Site 1601)
        • 接触:
          • Study Coordinator
          • 电话号码:48 12 2954135
    • Lower Silesian Voivodeship
      • Wroclaw、Lower Silesian Voivodeship、波兰、50-367
        • 完全的
        • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 1606)
    • Masovian Voivodeship
      • Warsaw、Masovian Voivodeship、波兰、02-781
        • 招聘中
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1608)
        • 接触:
          • Study Coordinator
          • 电话号码:+48225462223
    • Opole Voivodeship
      • Opole、Opole Voivodeship、波兰、45-061
        • 完全的
        • Szpital Wojewódzki w Opolu-Hematology Department ( Site 1607)
    • Pomeranian Voivodeship
      • Gdynia、Pomeranian Voivodeship、波兰、81-519
        • 完全的
        • Szpitale Pomorskie Sp. z o.o. ( Site 1600)
    • New South Wales
      • Sydney、New South Wales、澳大利亚、2747
        • 完全的
        • Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)
    • Victoria
      • Box Hill、Victoria、澳大利亚、3128
        • 招聘中
        • Box Hill Hospital ( Site 0203)
        • 接触:
          • Study Coordinator
          • 电话号码:+611300342255
    • Western Australia
      • Nedlands、Western Australia、澳大利亚、6009
        • 招聘中
        • Sir Charles Gairdner Hospital ( Site 0200)
        • 接触:
          • Study Coordinator
          • 电话号码:+61864573333
      • Dublin、爱尔兰、Dublin 9
        • 招聘中
        • Beaumont Hospital ( Site 2900)
        • 接触:
          • Study Coordinator
          • 电话号码:+35318092010
      • Limerick、爱尔兰、V94 F858
        • 主动,不招人
        • University Hospital Limerick ( Site 2903)
    • Canton Ticino
      • Bellinzona、Canton Ticino、瑞士、6500
        • 招聘中
        • Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 2302)
        • 接触:
          • Study Coordinator
          • 电话号码:+41918118540
    • Canton of Bern
      • Bern、Canton of Bern、瑞士、3010
        • 招聘中
        • Inselspital Bern ( Site 2303)
        • 接触:
          • Study Coordinator
          • 电话号码:+41316329023
      • Brasov、罗马尼亚、500052
        • 招聘中
        • Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802)
        • 接触:
          • Study Coordinator
          • 电话号码:0729075567
      • Iași、罗马尼亚、700483
        • 招聘中
        • Institutul Regional de Oncologie Iasi ( Site 1801)
        • 接触:
          • Study Coordinator
          • 电话号码:40374278811
    • Bucharest
      • Bucharest、Bucharest、罗马尼亚、030171
        • 招聘中
        • Spitalul Clinic Colțea ( Site 1805)
        • 接触:
          • Study Coordinator
          • 电话号码:0040213874100
    • Constanța County
      • Ovidiu、Constanța County、罗马尼亚、905900
        • 完全的
        • Ovidius Clinical Hospital ( Site 1804)
    • Arkansas
      • Springdale、Arkansas、美国、72762
        • 招聘中
        • Highlands Oncology Group ( Site 2728)
        • 接触:
          • Study Coordinator
          • 电话号码:479-872-8130
    • California
      • La Jolla、California、美国、92093-0698
        • 招聘中
        • University of California San Diego Moores Cancer Center ( Site 2717)
        • 接触:
          • Study Coordinator
          • 电话号码:858-534-5201
      • Torrance、California、美国、90502
        • 完全的
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)
    • Colorado
      • Denver、Colorado、美国、80218
        • 招聘中
        • Colorado Blood Cancer Institute ( Site 2726)
        • 接触:
          • Study Coordinator
          • 电话号码:720-754-4800
    • Kentucky
      • Louisville、Kentucky、美国、40202
        • 完全的
        • The University of Louisville, James Graham Brown Cancer Center ( Site 2729)
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • 主动,不招人
        • Mayo Clinic - Rochester ( Site 2706)
    • New Jersey
      • East Brunswick、New Jersey、美国、08816
        • 招聘中
        • Astera Cancer Care ( Site 2732)
        • 接触:
          • Study Coordinator
          • 电话号码:732-672-6405
      • Hackensack、New Jersey、美国、07601
        • 招聘中
        • John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)
        • 接触:
          • Study Coordinator
          • 电话号码:551-996-3003
    • North Dakota
      • Fargo、North Dakota、美国、58102
        • 完全的
        • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)
    • Texas
      • Dallas、Texas、美国、75390
        • 招聘中
        • UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)
        • 接触:
          • Study Coordinator
          • 电话号码:972-695-9450
    • Washington
      • Spokane、Washington、美国、99208
        • 招聘中
        • Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)
        • 接触:
          • Study Coordinator
          • 电话号码:509-462-2273
      • Manchester、英国、M20 4BX
        • 招聘中
        • The Christie NHS Foundation Trust ( Site 2602)
        • 接触:
          • Study Coordinator
          • 电话号码:01619561217
    • Bristol, City of
      • Bristol、Bristol, City of、英国、BS2 8ED
        • 招聘中
        • Bristol Haematology and Oncology Centre ( Site 2610)
        • 接触:
          • Study Coordinator
          • 电话号码:01173426733
    • England
      • Nottingham、England、英国、NG5 1PF
        • 招聘中
        • Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 2601)
        • 接触:
          • Study Coordinator
          • 电话号码:+441159691169
      • Windsor、England、英国、SL4 3HD
        • 招聘中
        • GenesisCare - Windsor ( Site 2608)
        • 接触:
          • Study Coordinator
          • 电话号码:+447989474250
    • London, City of
      • London、London, City of、英国、W1G 6AD
        • 招聘中
        • Sarah Cannon Research Institute UK ( Site 2612)
        • 接触:
          • Study Coordinator
          • 电话号码:02032195234
    • Oxfordshire
      • Oxford、Oxfordshire、英国、OX4 6LB
        • 招聘中
        • GenesisCare - Oxford ( Site 2607)
        • 接触:
          • Study Coordinator
          • 电话号码:+447989474250
    • Suffolk
      • Newmarket、Suffolk、英国、CB8 7XN
        • 招聘中
        • GenesisCare - Cambridge ( Site 2611)
        • 接触:
          • Study Coordinator
          • 电话号码:01223 655145
    • Surrey
      • Sutton、Surrey、英国、SM2 5PT
        • 招聘中
        • The Royal Marsden NHS Foundation Trust. ( Site 2606)
        • 接触:
          • Study Coordinator
          • 电话号码:020 8642 6011
      • Alicante、西班牙、03010
        • 招聘中
        • Hospital General Universitario de Alicante ( Site 2007)
        • 接触:
          • Study Coordinator
          • 电话号码:965 93 30 00
      • Barcelona、西班牙、08035
        • 招聘中
        • Hospital Universitari Vall d'Hebron ( Site 2001)
        • 接触:
          • Study Coordinator
          • 电话号码:+34934893806
      • Madrid、西班牙、28041
        • 招聘中
        • Hospital Universitario 12 de Octubre ( Site 2003)
        • 接触:
          • Study Coordinator
          • 电话号码:+34917792809
      • Madrid、西班牙、28222
        • 招聘中
        • Hospital Puerta de Hierro ( Site 2009)
        • 接触:
          • Study Coordinator
          • 电话号码:+34911916000
    • Barcelona
      • L'Hospitalet de Llobregat、Barcelona、西班牙、08908
        • 招聘中
        • Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 2000)
        • 接触:
          • Study Coordinator
          • 电话号码:+34932607750
    • Castille and León
      • Salamanca、Castille and León、西班牙、37007
        • 招聘中
        • Hospital Universitario de Salamanca ( Site 2002)
        • 接触:
          • Study Coordinator
          • 电话号码:34923 29 11 00x55974
    • La Coruna
      • A Coruña、La Coruna、西班牙、15006
        • 招聘中
        • CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2005)
        • 接触:
          • Study Coordinator
          • 电话号码:34981178000
      • Caba、阿根廷、C1114AAN
        • 招聘中
        • FUNDALEU ( Site 0104)
        • 接触:
          • Study Coordinator
          • 电话号码:5411 48771046
      • Córdoba、阿根廷、X5016KEH
        • 招聘中
        • Hospital Privado Universitario de Córdoba ( Site 0107)
        • 接触:
          • Study Coordinator
          • 电话号码:+541569634187
      • Mendoza、阿根廷、M5500AYB
        • 完全的
        • Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires、Buenos Aires、阿根廷、C1118AAT
        • 招聘中
        • Hospital Aleman ( Site 0102)
        • 接触:
          • Study Coordinator
          • 电话号码:+541148277000
    • Buenos Aires F.D.
      • Buenos Aires、Buenos Aires F.D.、阿根廷、C1431FWO
        • 招聘中
        • Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)
        • 接触:
          • Study Coordinator
          • 电话号码:+541152990247
    • Santa Fe Province
      • Rosario、Santa Fe Province、阿根廷、S2000DEJ
        • 招聘中
        • Fundacion Estudios Clinicos ( Site 0112)
        • 接触:
          • Study Coordinator
          • 电话号码:+54 0341 238 4171
      • Seoul、韩国、03722
        • 招聘中
        • Severance Hospital Yonsei University Health System ( Site 2201)
        • 接触:
          • Study Coordinator
          • 电话号码:+82222281972
      • Seoul、韩国、06351
        • 招聘中
        • Samsung Medical Center ( Site 2200)
        • 接触:
          • Study Coordinator
          • 电话号码:+82234106548

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment)
  • Has a life expectancy of at least 3 months, based on the investigator assessment
  • Has the ability to swallow and retain oral medication
  • Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
  • Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • Has adequate organ function
  • Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention
  • Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention
  • Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is >350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART

Part 1 and Part 2 (Cohorts A to C and J)

  • Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with

    • At least 2 lines of prior therapy (Part 1 only)
    • Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi), and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines
    • Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive
    • Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy
    • Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible BTKi (all three classes of therapies are required) will be enrolled into Cohort J
    • Has active disease for CLL/SLL clearly documented to initiate therapy
    • For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate at Screening (optional for participants enrolling in Part 1)

Part 2 (Cohorts D to G)

- Has a confirmed diagnosis of and meets the following prior therapy requirements:

  • Participants with Richter's transformation who are relapsed or refractory following at least 1 line of prior therapy (Cohort D)
  • Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E)
  • Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen
  • Participants with Follicular lymphoma (FL) who are relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen) (Cohort G)
  • Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral Computed tomography (CT) scan
  • Has a lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate (Cohort D) at Screening

Part 2 (Cohort H): confirmed diagnosis of Waldenström's macroglobulinemia (WM); participants who are relapsed or refractory to standard therapies for WM including chemoimmunotherapy and a covalent irreversible BTKi

  • Has active disease defined as 1 of the following: systemic symptoms, physical findings, laboratory abnormalities, coexisting disease
  • Has measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis); IgM ≥450 mg/dL; or bone marrow infiltration of 10%
  • Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis at Screening or a lymph node biopsy from an archival

Exclusion Criteria:

  • Has active HBV/HCV infection (Part 1 and Part 2)
  • Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen <10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded
  • Has active central nervous system (CNS) disease
  • Has an active infection requiring systemic therapy
  • Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
  • Has any clinically significant gastrointestinal abnormalities that might alter absorption
  • History of severe bleeding disorders

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Nemtabrutinib

Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation.

Nemtabrutinib tablets administered orally QD.

其他名称:
  • MK-1026
  • 请求请求 531

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)
大体时间:Up to ~56 days (Cycles 1-2, cycle = 28 days)

DLTs will be defined as toxicities observed during the first 2 cycles (8 weeks) of Part 1 and include: Grade ≥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting ≥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting >7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for >1 week (with exceptions); missing >25% of nemtabrutinib doses as a result of drug-related adverse events (AEs) during the first 2 cycles (8 weeks); Grade 5 toxicity.

Up to ~56 days (Cycles 1-2, cycle = 28 days)
Part 1: Number of participants experiencing adverse events (AEs)
大体时间:Up to ~71 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1.

Up to ~71 months
Part 1: Number of participants discontinuing study treatment due to AEs
大体时间:Up to ~42 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 1.

Up to ~42 months
Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)
大体时间:Up to ~61 months

ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR), or partial response (PR). CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~61 months
Part 2: ORR per Lugano criteria 2014 as assessed by ICR
大体时间:Up to ~61 months

ORR per Lugano criteria 2014 is defined as the percentage of participants achieving a CR or PR. CR defined as EITHER CR by imaging (computed tomography [CT]): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR complete metabolic response (CMR): score of 1, 2 or 3 on the 5-point scale assessing fluorodeoxyglucose (FDG) metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver) AND bone marrow (BM) normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the sum of the product of diameters [SPD] of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR Partial Metabolic Response (PMR) with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities.

Up to ~61 months
Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICR
大体时间:Up to ~71 months

ORR per IWWM criteria 2014 is defined as the percentage of participants achieving a CR, very good partial response (VGPR), or PR. CR is defined as all lymph nodes are normal in size (none ≥15 mm), liver and spleen normal in size, serum immunoglobulin M (IgM) values in the normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with a second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal).

Up to ~71 months

次要结果测量

结果测量
措施说明
大体时间
Part 1: Area Under the Curve (AUC) of Nemtabrutinib
大体时间:At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 1: Minimum Concentration (Cmin) of Nemtabrutinib
大体时间:At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 1: Maximum Concentration (Cmax) of Nemtabrutinib
大体时间:At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 1: ORR per iwCLL criteria 2018 as assessed by ICR
大体时间:Up to ~71 months

ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a CR, CRi, nPR, or PR. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~71 months
Part 1: Duration of Response (DOR) per iwCLL criteria 2018 as assessed by ICR
大体时间:Up to ~71 months

For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~71 months
Part 2: Number of participants experiencing AEs
大体时间:Up to ~61 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2.

Up to ~61 months
Part 2: Number of participants discontinuing study treatment due to AEs
大体时间:Up to ~42 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 2.

Up to ~42 months
Part 2: AUC of Nemtabrutinib
大体时间:At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 2: Cmin of Nemtabrutinib
大体时间:At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 2: Cmax of Nemtabrutinib
大体时间:At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 2: DOR per iwCLL criteria 2018 as assessed by ICR
大体时间:Up to ~61 months

For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~61 months
Part 2: DOR per Lugano criteria 2014 as assessed by ICR
大体时间:Up to ~61 months

For participants with CR or PR per Lugano criteria 2014, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as EITHER CR by imaging (CT): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR CMR: score of 1, 2 or 3 on the 5-point scale assessing FDG metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver and/or new lesions) AND BM normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the SPD of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR PMR with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities.

Up to ~61 months
Part 2: DOR per IWWM criteria 2014 as assessed by ICR
大体时间:Up to ~61 months

For participants with CR, VGPR, or PR per IWWM criteria 2014, DOR defined as the time from first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as all lymph nodes normal in size (none ≥15 mm), liver and spleen normal in size, serum IgM values in normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal).

Up to ~61 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Medical Director、Merck Sharp & Dohme LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年4月5日

初级完成 (估计的)

2029年1月4日

研究完成 (估计的)

2029年1月4日

研究注册日期

首次提交

2021年1月25日

首先提交符合 QC 标准的

2021年1月25日

首次发布 (实际的)

2021年1月28日

研究记录更新

最后更新发布 (实际的)

2026年10月27日

上次提交的符合 QC 标准的更新

2026年10月23日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • 1026-003
  • MK-1026-003 (其他标识符:MSD)
  • 2020-002324-36 (EudraCT编号)
  • U1111-1290-4004 (注册表标识符:UTN)
  • 2023-504931-42-00 (注册表标识符:EU CT)
  • 2023 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅